Innovative
Medicine
for everyone
everywhere

ADOCIA

innovative medicine
for everyone, everywhere

Corporate Presentation

October 2023

Forward-looking statements

This corporate presentation (the “Presentation”) has been prepared by ADOCIA S.A. (the “Company” and, together with its subsidiary, the “Group”) and is provided for information purposes only. It is not for promotional use. References herein to the Presentation shall mean and include this document, any oral presentation accompanying this document provided by the Group, any question and answer session following that oral presentation and any further information that may be made available in connection with the subject matter contained herein (together with the information, statements and opinions contained in this Presentation, the “Information”).

The Information is provided as of the date of the Presentation only and may be subject to significant changes at any time without notice. The Group does not undertake any obligation to update the Information.

The Information has not been independently verified. Subject to applicable law, none of the Group or its advisors accepts any responsibility whatsoever and makes no representation, warranty or undertaking, express or implied, is made as to the , as to the fairness, accuracy, completeness or appropriateness of the Information

The Presentation contains information on the Group’s markets and competitive position, and more specifically, on the size of its markets. This information has been drawn from various sources or from the Group’s own estimates. Investors should not base their investment decision on this information.

The Presentation does not purport to contain comprehensive or complete information about the Group and is qualified in its entirety by the business, financial and other information that the Company is required to publish in accordance with the rules, regulations and practices applicable to companies listed on Euronext Paris including in particular the risk factors described in in the most recent Company’s Universal Registration Document filed with the French Financial Markets Authority (Autorité des Marchés Financiers), in any other periodic report and in any other press release, which are available free of charge on the websites of the Group (www.adocia.com) and/or the AMF (www.amf-france.org).

The Information contains certain forward-looking statements. These statements are not guarantees of the Group's future performance. These forward-looking statements relate without limitation to the Group's future prospects, developments and marketing strategy and are based on analyses of earnings forecasts and estimates of amounts not yet determinable. Forward-looking statements are subject to a variety of risks and uncertainties as they relate to future events and are dependent on circumstances that may or may not materialize in the future.

Forward-looking statements cannot, under any circumstance, be construed as a guarantee of the Group's future performance as to strategic, regulatory, financial or other matters and the Group’s actual performance, including its financial position, results and cash flow, as well as the trends in the sector in which the Group operates, may differ materially from those proposed or reflected in the forward-looking statements contained in the Information.

Even if the Group’s performance, including its financial position, results, cash-flows and developments in the sector in which the Group operates were to conform to the forward-looking statements contained in the Presentation, such results or developments cannot be construed as a reliable indication of the Group's future results or developments. The Group does not undertake any obligation to update or to confirm projections or estimates made by analysts or to make public any correction to any prospective information in order to reflect an event or circumstance that may occur after the date of the Presentation.

The Information does not constitute an offer to sell or subscribe or a solicitation to purchase or subscribe for securities, nor shall there be any sale of these securities in the United States or any other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. No public offering of securities may be conducted in any member state of the European Economic Area (including France) prior to the publication in the relevant member state of a prospectus that complies with the provisions of Regulation 2017/119.

All persons accessing the Information are deemed to agree to all the limitations and restrictions set out above.

Adocia at a glance

1. **Mission:** Development of **innovative formulations** of approved peptides and novel cell therapy approaches for **diabetes and obesity**

2. **Business model: Licensing-out/Partnering** our products and technologies after proof-of-concept in animal and/or human model

3. **2 partnerships with large pharma players**
   - **Tonghua Dongbao:** BC Lispro (Ph. 3) and BC Combo (Ph. 1) **out-licensed for Asia**
   - **Sanofi: Exclusive rights** on M1Pram (Ph. 2), in view of a global partnership

4. **Assets: 3 specialty products** in clinics (Ph. 1 to 3) and **4 proprietary technology** platforms, supporting a balanced pipeline

5. **€16.8m** cash on-hand as of September 30, 2023

Highly experienced management team

Gérard Soula
PhD, MBA

President
Co-founder

Rhône-Poulenc · Avadel

Olivier Soula
PhD, MBA

CEO
Co-founder

Avadel

Valérie Danaguezian

Chief Financial Officer

Deloitte · sanofi · Avadel

Jérémy Benattar
PharmD, Eng

Marketing & Strategy Director

Otsuka · Ethypharm · AstraZeneca

Rosy Eloy
MD

Chief Medical Officer

Inserm · Geistlich · NAMSA

- Co-founded by Gérard, Olivier and Rémi Soula in 2005
- IPO on Euronext-Paris in 2012
- 80+ employees mostly dedicated to R&D incl. c. 35 PhDs/MDs
- Located in Lyon, France

Business Strategy: solid partnerships and promising projects

Partnerships:
Agreements on 3 products with pharma leaders in insulins

Proprietary Products to be licensed:
Market potential: multi-billion $USD

Proprietary Technology Platforms:
Business Model: Feasibility study before partnership

BC Lispro & BC Combo
Future milestones (80M$) + royalties
通化東宝 Tong Hua Dong Bao Group

M1Pram
Exclusive negotiation rights in view of a global partnership
sanofi

BC Lispro EU/US
Ph. 3 ready

AdoShell Islets
Animal POC

AdOral Sema
Animal POC

BioChaperone

AdoShell

AdOral

AdoGel

A diversified specialty products pipeline

Diabetes

Obesity

		Preclinic	Phase 1	Phase 2	Phase 3	Status / Upcoming milestones	Partner
BC Lispro	Ultra-Rapid Insulin					Phase 3 in China ongoing Phase 3 in USA and Europe ready to start*	通化東宝 Tong Hua Dong Bao Group Asia & other territories
BC Combo	Insulins Combination Long acting + Rapid acting					Phases 1 completed – Preparation of next clinical steps	
AdoShell Islets	Islets of Langerhans transplant - Cell Therapy					2023 First in Human preparation	
M1Pram	Insulin-pramlintide combination					Exclusive rights on all insulin-pramlintide combination granted to Sanofi to negotiate a global partnership	sanofi
BC LisPram							
AdOral Sema	Oral Delivery of GLP-1					2024 First in Human*	
AdoGel	Long-Acting Injectable					2023 animal POC	

BC: BioChaperone®; **Lispro:** insulin lispro; **BC Combo:** BC insulin glargine insulin lispro; **M1**: A21G human insulin; **Pram**: pramlintide; **Sema :** semaglutide, **POC:** Proof of Concept
* upon partnership signature

Adocia's partnering models are based on proprietary technology platforms with strong IP strategy

BioChaperone®

- Pharmaceutical excipient
- Forms a complex with therapeutic peptides
  - ➔ Accelerates absorption
  - ➔ Protects against enzymatic degradation
  - ➔ Improves solubility
  - ➔ Improves stability
- Value:
  - ➔ Improves proteins/peptides efficacy
  - ➔ Combines hormones in one single product

AdOral®

- Pharmaceutical excipient
- Enhances peptides oral route of administration
  - ➔ Improves bioavailability
- Value:
  - ➔ Avoids injections and provides unique competitive advantage vs. injectables peptides
  - ➔ Life cycle management of existing injectable products
  - ➔ Avoids large scale sterile manufacturing of injectables

AdoShell®

- Hydrogel scaffold
- Cells encapsulation for cell therapies
  - ➔ Protects grafted cells from immune system rejection
  - ➔ Ensures retrievability and easy surgical implantation
- Value:
  - ➔ Avoids immunosuppressive therapies associated to cell therapies

AdoGel®

- Biomaterial
- Long-acting drug delivery of small molecules or biologics
  - ➔ Release from 1 to 36 months, without initial burst, for local or systemic use
- Value:
  - ➔ Avoids repetitive drug administrations
  - ➔ Improves compliance

Adocia has a strong track record in preclinical and clinical development up to Phase 3 of specialty products based on innovative technologies

Diabetes and Obesity: worldwide chronic pandemics

537 million people live with **diabetes**[1]

1 in 11



1.9 billion are **overweight** or **obese**[2]

1 in 4



Diabetes is closely linked to obesity

- In the US, **65%** of adults with type 1[3] diabetes, and **85%** of type 2[4] are overweight or obese, making **DIABESITY** a new pandemic



Adocia is developing unique formulations of these key hormones to improve diabetes and obesity treatments

1. IDF Atlas, 10th Edition, 2021
2. WHO
3. Conway et al, Diabetes Med 2010 April; 27(4):398-404. BMI>25, Data for 2004-2007 period
4. Epidemiology of Obesity and Diabetes and Their Cardiovascular Complications



Proprietary specialty products based on approved drugs



BioChaperone® Lispro

Ultra-Rapid Acting Insulin for a tighter glycemic control

BC Lispro has competitive advantages in the Ultra-Rapid Insulin class

- Better efficacy profile for less hyperglycemia and less hypoglycemia ("Faster-in" / "Faster-out") vs. comparators
- Good tolerance for optimized daily use
- Range of strengths (U100 & U200), adapted to pump miniaturization and patients' requirements

Post-meal glycaemia in T1D



The combination of a faster release with a good local tolerance will put BC Lispro in a strong position to compete with other Ultra Rapid Insulins

Trial in 38 subjects with type 1 diabetes (NCT#02213146) ; *CI-95% for LSM ratio
These results were the subject of an oral presentation by Dr Tim Heise (Profil Neuss) during the 76th Scientific Sessions of the American Diabetes Association (June 2016).

BC Lispro in phase 3 program in China with Tonghua Dongbao

Market

- Insulin and analogs in China: c. **$4 billion**

Partnership with Tonghua Dongbao (2018)

- Licensed for development & commercialization for China and other Asian territories[2]:
  - ✓ $10m upfront
  - ✓ $ 5m milestone - 1st patient on the Phase 3 trial (Q2 2022)
  - $30m development and approval milestones
    - Next milestone: end of Phase 3 - $10m
  - Double-digit royalties
- Global supply agreement for GMP lispro for the development and commercialization of BC Lispro outside licensed territories

通化東宝
Tong Hua Dong Bao Group



Project status

- ✓ Phase 3 clinical program **on track** in China. Completion expected in 2024
- ✓ Phase 3-ready for US/EU, with green light from FDA/EMA

BC Lispro will be the next generation of mealtime insulin in China

1. Adocia estimates based on major companies' 2021 annual reports
2. China and other territories (excluding US, EU, Japan)
3. Data THDB
4. June 2022



BC Combo, glargine-lispro premix

The best insulin premix

BC Combo, a unique combination of glargine and lispro, the gold standards of basal and prandial insulins

BioChaperone® Combo

1 product
Once or twice a day
U200 fixed ratio
(150 U/mL glargine - 50 U/mL lispro)

- ☑ Simple
- ☑ Affordable
- ☑ Limited number of injections
- ☑ Improved glycemic control



Trial in 28 people with T1D (NCT#02514954); * $p=3.10^{-3}$;** $p=8.10^{-3}$

BC Combo offers better performance than Humalog® Mix, current standard of care on the premix market

1. Adocia estimates, based on market leaders' annual reports and IQVIA MIDAS data 2019

BC Combo is licensed to Tonghua Dongbao in China

Premix market

Western Markets:
T2D patients

$2.7bn[1]

Emerging Markets:
T1D & T2D patients

$2.3bn[1]

~65%
Market share in **India and China** (volume)[1]

Tonghua Dongbao deal

通化東宝
Tong Hua Dong Bao Group

- ✓ **$40m upfront**
- **$50m upcoming** development milestones
  - Next milestone: $10m to be received at start of Phase 3
- **Double-digit royalties** on sales

Positive results obtained on the 3 clinical studies conducted in Europe
Preparation of the next clinical phases, to be conducted in China.

1. Adocia estimate based on major companies' annual reports 2019
2. China and other territories (excluding US, EU, Japan)
3. Data THDB



M1Pram
Insulin & Amylin analogs combination

Breakthrough treatment to address the unmet medical need of overweight patients living with diabetes

Agreement with Sanofi on M1Pram

On July 5, 2023,

- **Adocia received €10m payment from Sanofi** in exchange of an exclusive negotiation right on **M1Pram**
- Sanofi commitment will contribute **to accelerate M1Pram clinical development**
- Sanofi agreement covers any programs related to **insulin / pramlintide combinations**

Adocia and Sanofi objective is to establish a **global partnership on M1Pram**

M1Pram, a bi-hormonal therapy to treat people with obesity and diabetes



Obesity is a main concern for patients under **intensive insulin therapy**, affecting 43 million patients

Amylin is missing in people with insulin-dependent diabetes, and it contributes to diabetes dysregulations



Amylin exerts important physiological effects on metabolism and weight control

1. Activates amylin receptors in different brain areas

Satiety, well-being, cognitive functions protection

2. Inhibits glucagon secretion

Better glycemic control, lower PPG rise

3. Slows gastric emptying

Synchronize insulin arrival with BG rise



Reestablishing the physiologic equilibrium between insulin and amylin offers strong clinical benefits

PPG: Prost-Prandial Glucose, BG: Blood Glucose

Source: Adapted from Kruger D, et al. Diabetes Educ. 1999;25:389-397

M1Pram reduces body weight with high efficacy in T1D with obesity

CT041 : Phase 2 study – M1Pram vs. lispro (Humalog®) - type 1 diabetes - 16 weeks ambulatory



All patients BMI ≥ 25 kg/m²
(*p* value = 0.001)

-0.15 kg
lispro control arm (n=36)

-2.5 kg
M1Pram (n=34)

BMI ≥ 30 kg/m²
(*post hoc*, *p* value = 0.03)

-0.57 kg
lispro control arm (n=9)

-5.56 kg
M1Pram (n=7)

M1Pram could be the answer to the unmet medical need of obesity in T1D

BMI: Body Mass Index

Body weight loss with M1Pram in T1D is comparable with insulin plus Semaglutide or Tirzepatide treatment in T2D

Change from baseline in body weight at W16

Semaglutide **- 4.55 kg vs. - 1.08 kg**



T2D taking basal insulin
Mean BMI 32 kg/m² [19-51]
N=396 (3 arms)
Novo Nordisk Sustain 5 study

Tirzepatide **- 5.6 kg vs. + 0.4 Kg**



T2D taking glargine
Mean BMI 33.4 kg/m²
N=475 (4 groups)
E. Lilly Surpass 5 study

ADOCIA

Maintained glycemic control, with 21% reduction in prandial insulin dose

	Change from baseline* Mean (SD)		*P*-value
	M1Pram	Lispro	
HbA_{1c} (%)	0.14 (0.51)	0.10 (0.51)	0.81 (NS)
Time-In-Range 70-180 mg/dL (%)	-3.17 (8.76)	-1.54 (8.87)	0.29 (NS)
Prandial insulin dose (U/d)	-5.97(6.18)	-0.61(7.08)	**<0.001**

While M1Pram reduces weight, it maintains same performance than Humalog (standard of care)

* Baseline: 3 week assessment before treatment
  Results: 3 last week assessment of the 16 week treatment period

Medical value of M1Pram is confirmed

- ✓ Significant weight loss demonstrated & satiety effect
- ✓ Glycemic control maintained, without increase of hypoglycemia
- ✓ Sparing effect on prandial insulin dose
- ✓ Product well tolerated and safe
- ✓ Easy-to-use: one product injected at mealtime
- ✓ Excellent patient satisfaction reported

These attributes will allow M1Pram to serve a multi-billion-dollar market

M1Pram generates high expectations from KOLs

"The phase 2 study of M1Pram shows that a single injection with each meal is as easy to use and as efficient as Humalog for glycemic control without increasing the rate of hypoglycemia. In addition, weight control is challenging for T1D patients, potentially limiting glycemic control and adding cardiovascular risk. While reducing insulin requirement, M1Pram improved appetite control and had a beneficial effect on weight, particularly in obese T1D patients. These features support a future role for this combination formulation for T1D."

Dr. Matt Riddle, Professor of Medicine, Oregon Health & Science University



"This combination has the potential to finally deliver on the promise of pramlintide for a large number of patients."

Prof. Robert Ratner, Georgetown University Washington DC

"The glycemic results with M1Pram (P1b) are quite promising as is the observed weight loss, which is important given the characteristics of the population taking prandial insulin. I look forward to the next series of clinical trials."

Jay S. Skyler, Professor of Medicine, University of Miami Leonard M. Miller School of Medicine

"Remarkably, after only 3 weeks of treatment with M1Pram (P1b), all known pharmacological effects of pramlintide were observed."

Prof. Thomas Pieber, Medical University of Graz, Austria



AdoShell® Islets

Immunoprotective scaffold for islets of Langerhans transplantation to cure Type 1 Diabetes

Islets transplantation has changed lives of patients living with unstable diabetes, but it still has many limitations

- Among 40 million people living with T1D worldwide, **75 000** have a form particularly unstable (sometimes called “brittle”)
  - Life expectancy 27- to 45-year-old
  - Approx. 1,000 cases in France (3 unstable T1D / 1,000 T1D)

- Transplantation of Islets of Langerhans is the only curative treatment available
  - Validated by French Health Authority (HAS) since 2020
  - FDA approved 1st pancreatic islet cellular therapy to treat T1D patients in July 2023

Transplantation is effective but is rarely applied to T1D because of the adverse effects of immunosuppressive treatments

Data source: A. Cartwright, et al., The outcome of brittle type 1 diabetes—a 20-year study, *QJM: An International Journal of Medicine*, Volume 104, Issue 7, July 2011, Pages 575–579

AdoShell®, an immuno-protective scaffold for islets of Langerhans transplantation for diabetes

Hydrogel Reagents



Insulin secreting cells

- 1st generation: islets of Langerhans from **deceased donors**
- 2nd generation: from **stem cells**

AdoShell Islets





Immuno-isolation

Ab, T cells

Large entities > 10 nm





Free diffusion

Oxygen, Glucose, Insulin

Small entities < 5 nm



AdoShell® could ensure cell engraftment and long-term functionality in the absence of immunosuppression

AdoShell® : An ultra-thin, immuno-protective hydrogel film for cells encapsulation

High water content for cell compatibility	✓
Immuno-isolating gel	✓
Ultra-thin aseptic film	✓
High cell density for miniaturization	✓
Biocompatible	✓
Mechanically resistant	✓
Implantable by mini-invasive surgery	✓
Retrievable by mini-invasive surgery	✓
Long term stability	✓

Technology patented

First AdoShell application for cell therapy is to provide a cure for diabetes

POC in diabetic rat: glycemia controlled during a 132-day study without immunosuppressor

1. **Transplantation of AdoShell containing allogenic islets** in diabetic rat peritoneum at day 0
2. **Explantation** of the implant at day 132. Sacrifice of control group at day 35



Next step: proof of concept in large animal model, paving the way for a first in human study

AdoShell provides a platform, opening to many cell therapy markets

- AdoShell scaffold displays key attributes enabling to progress towards new and more effective cell therapies:
  - ✓ No need of immunosuppressors
    - No need of gene-editing strategy for immune-evasive iPSCs
  - ✓ Safe and efficient cell engraftment
  - ✓ Safely removable and replaceable implant
  - ✓ Containment of proliferative cells

- Application of AdoShell to other pathologies is vast, considering different cell sources:
  - ✓ Stem cells
  - ✓ Engineered cells for therapeutic proteins delivery (cell factory)

Adocia is looking to partner with companies working in cell therapy

iPSCs: induced pluripotent stem cells



AdOral®

A promising technology for oral delivery of peptides

Only 5 peptide therapeutics have been approved for oral delivery in a growing market dominated by injectable forms

Global Peptide Therapeutics Market* ($)

*mAb excluded from the analysis



Data Source: Global Data

Cyclosporin
1.2 kDa
Approved 1995



Voclosporin
1.2 kDa
Approved, 2021



Octreotide
1.0 kDa
Approved 2020



Desmopressin
1.1 kDa
Approved 1978





Semaglutide
4.1 kDa
Approved 2019

There is a huge market opportunity to develop AdOral, a new technology for oral delivery to replace injections of peptides

AdOral: a promising technology for oral delivery of peptides

AdOral is a unique formulation based on a new type of permeation enhancer (PE) combined with peptide protection against degradation

Technology patented until 2042 globally

The technology has been validated with Semaglutide compared to Rybelsus®, an oral formulation for Type 2 diabetes treatment

Potential applications to other peptides or proteins

A first feasibility study is ongoing on a partner's protein
Two other feasibility studies are under discussion

Semaglutide formulated with AdOral has shown significantly improved bioavailability in animal



Bioavailability of semagludide formulated with AdOral:
5-fold higher median than Rybelsus

Adocia seeks to establish proof of concept with peptides from future partners



AdoGel®

Long-acting drug delivery platform

AdoGel, a biomaterial for ultra long delivery of therapeutic agents

Adocia is developing a soft tissue-like biomaterial for sustained release of small molecules/biologics

- Pharmaceutic forms
  - Implantable & Removable device
  - Injectable (*in-situ* forming gel)
- Main properties
  - **Release Duration**: from 1 month and up to 36 months
  - **Pharmacokinetics**: pseudo zero-order, no burst
  - **Local or systemic delivery**
- Potential to release different types of APIs
  - Small molecules: contraceptives, anti-HIV, anti-cancer drugs, …
  - Peptides & Proteins: monoclonal Ab, GLP-1, PTH, …

Implantable device



Injection and in-situ forming gel

First showcase application: AdoGel with Levonorgestrel (LNG)

First application: sustained release of Levonorgestrel (LNG) over 180 days after SC administration in animal model

Mean (±SE) PK profile



Cumulative absorption



AdoGel Preclinical proof of concept is ongoing with LNG
Additional showcase studies are also ongoing with antibodies
Adocia is offering this technology to partners, for application on their proprietary molecules

Financial & news flow

News flow

BC Lispro

- In China (with partner THDB): **Phase 3 ongoing**
  - Phase 3 completion expected 2024
  - $10m milestones payment
- In USA/EU: **Phase 3 ready to be launched** under partnering condition

BC Combo

- Positive results on THDB's insulins qualification **clinical studies in Europe**
  - Next step: dossier filing for **Phase 3 authorization** expected in 2024
  - $10m to be received at Phase 3 initiation

M1Pram and related projects

- **Exclusive negotiation rights granted to Sanofi** in view of a global partnership

AdoShell® Islets

- First-in-human study preparation in 2023

AdoGel®

- Preclinical Proof of Concept in 2023

AdOral®

- First-in-human study expected in 2024 under partnering condition

THDB : Tonghua Dongbao

Key financials & shareholder information

Key financials features

Already received
- **€95m** raised since inception
- **$135m** received from partnerships

Expected payment
- **$80m** as per contract with THDB + royalties

End of September 2023
Cash position: 16.8m€
Debt (excl. derivatives and IFRS16): 5.6m€

Shareholder ownership

As of Oct. 25th, 2023



Market information

- Listed on Euronext Paris (ADOC)
- 13.9 shares outstanding
- ADR program in the US (ADOCY)

ADOC LISTED EURONEXT

ELIGIBLE PEA PME

Analyst coverage
- Kepler Chevreux – Julie Telliez
- Oddo - Oussema Denguir

THDB : Tonghua Dongbao

Summary

- Adocia's projects are based on **4 proprietary technologies:** BioChaperone®, AdOral®, AdoShell®, AdoGel®

- Adocia is seeking to license-out the assets from its well-advanced and diversified pipeline:
  - Key **products** in ongoing **clinical trials:**
    - **BC Lispro: Phase 3** in China
    - **BC Combo:** positive results on 3 clinical trials for qualification of Tonghua Dongbao's insulins
    - **M1Pram:** Exceptional weight loss **in Phase 2** – Exclusivity right granted to Sanofi in view of a global partnership
  - Proprietary innovative **technology platforms**, with applications at **preclinical stage**:
    - **AdoShell® Islets**, an immuno-protective scaffold for cell therapy for diabetes
    - **AdOral® Sema**, for oral delivery of semaglutide
    - **AdoGel®**, for long-acting delivery of small molecules (LNG) and peptides (semaglutide)

- **$80m** in development milestones to come from **Tonghua Dongbao partnership** ($20m expected in 2024)
- Cash position: **€16.8m**[1]

1. As of 09/30/2023

Innovative
Medicine
for everyone
everywhere



Thank you
for your kind interest

115 avenue Lacassagne
69003 Lyon – FRANCE
Ph.:+33 4 72 610 610
contact@adocia.com